

**Amendments to the Claims:**

This listing of claims will replace all prior versions and listings of claims in the application.

**Listing of Claims:**

1. **(Previously Presented)** A compound selected from the group consisting of:  
[4-(2-Amino-4-methyl-thiazol-5-yl)-pyrimidin-2-yl]-(3-nitro-phenyl)-amine [1];  
[4-(2-Amino-4-methyl-thiazol-5-yl)-pyrimidin-2-yl]-(4-trifluoromethyl-phenyl)-amine [7];  
[4-(2-Amino-4-methyl-thiazol-5-yl)-pyrimidin-2-yl]-(4-methoxy-phenyl)-amine [8];  
[4-(2-Amino-4-methyl-thiazol-5-yl)-pyrimidin-2-yl]-(3-chloro-phenyl)-amine [9];  
[4-(2-Amino-4-methyl-thiazol-5-yl)-pyrimidin-2-yl]-(3-iodo-phenyl)-amine [10];  
[4-(2-Amino-4-methyl-thiazol-5-yl)-pyrimidin-2-yl]-(4-iodo-phenyl)-amine [11];  
[4-(2-Amino-4-methyl-thiazol-5-yl)-pyrimidin-2-yl]-(4-fluoro-phenyl)-amine [12];  
[4-(2-Amino-4-methyl-thiazol-5-yl)-pyrimidin-2-yl]-(3-bromo-phenyl)-amine [16];  
[4-(2-Amino-4-methyl-thiazol-5-yl)-pyrimidin-2-yl]-(4-bromo-phenyl)-amine [17];  
N-{4-Methyl-5-[2-(3-nitro-phenylamino)-pyrimidin-4-yl]-thiazol-2-yl}-methanesulfonamide [56];  
2-{4-Methyl-5-[2-(3-nitro-phenylamino)-pyrimidin-4-yl]-thiazol-2-ylamino}-ethanol [58];  
2-{5-[2-(4-Fluoro-phenylamino)-pyrimidin-4-yl]-4-methyl-thiazol-2-ylamino}-ethanol [59];  
2-Chloro-N-{4-methyl-5-[2-(3-nitro-phenylamino)-pyrimidin-4-yl]-thiazol-2-yl}-acetamide [60];  
2-Chloro-N-{5-[2-(4-fluoro-phenylamino)-pyrimidin-4-yl]-4-methyl-thiazol-2-yl}-acetamide [61];  
[4-(2-Amino-4-methyl-thiazol-5-yl)-pyrimidin-2-yl]-(4-nitro-phenyl)-amine [63];  
[4-(2-Amino-4-methyl-thiazol-5-yl)-pyrimidin-2-yl]-(phenyl)-amine [64]; and  
4-[4-(2-Amino-4-methyl-thiazol-5-yl)-pyrimidin-2-yl]-benzenesulfonic acid [65]; or a pharmaceutically acceptable salt thereof.

2. **(Previously Presented)** A compound according to claim 1, selected from the group consisting of:  
[4-(2-Amino-4-methyl-thiazol-5-yl)-pyrimidin-2-yl]-(3-nitro-phenyl)-amine [1];

[4-(2-Amino-4-methyl-thiazol-5-yl)-pyrimidin-2-yl]-(3-chloro-phenyl)-amine [9];  
[4-(2-Amino-4-methyl-thiazol-5-yl)-pyrimidin-2-yl]-(3-iodo-phenyl)-amine [10];  
N-{4-Methyl-5-[2-(3-nitro-phenylamino)-pyrimidin-4-yl]-thiazol-2-yl}-  
methanesulfonamide [56];  
2-{4-Methyl-5-[2-(3-nitro-phenylamino)-pyrimidin-4-yl]-thiazol-2-ylamino}-ethanol  
[58];  
2-Chloro-N-{4-methyl-5-[2-(3-nitro-phenylamino)-pyrimidin-4-yl]-thiazol-2-yl}-  
acetamide [60]; and  
2-Chloro-N-{5-[2-(4-fluoro-phenylamino)-pyrimidin-4-yl]-4-methyl-thiazol-2-yl}-  
acetamide [61], or a pharmaceutically acceptable salt thereof.

**3. (Previously Presented)** A compound according to claim 2, selected from the group consisting of:

2-Chloro-N-{4-methyl-5-[2-(3-nitro-phenylamino)-pyrimidin-4-yl]-thiazol-2-yl}-  
acetamide [60]; and  
2-Chloro-N-{5-[2-(4-fluoro-phenylamino)-pyrimidin-4-yl]-4-methyl-thiazol-2-yl}-  
acetamide [61], or a pharmaceutically acceptable salt thereof.

**4. (Currently Amended)** A compound according to claim 12, selected from the following:

[4-(2-Amino-4-methyl-thiazol-5-yl)-pyrimidin-2-yl]-(3-nitro-phenyl)-amine [1];  
[4-(2-Amino-4-methyl-thiazol-5-yl)-pyrimidin-2-yl]-(3-chloro-phenyl)-amine [9];  
[4-(2-Amino-4-methyl-thiazol-5-yl)-pyrimidin-2-yl]-(3-iodo-phenyl)-amine [10];  
[4-(2-Amino-4-methyl-thiazol-5-yl)-pyrimidin-2-yl]-(3-bromo-phenyl)-amine [16];  
N-{4-Methyl-5-[2-(3-nitro-phenylamino)-pyrimidin-4-yl]-thiazol-2-yl}-  
methanesulfonamide [56]; and  
2-{4-Methyl-5-[2-(3-nitro-phenylamino)-pyrimidin-4-yl]-thiazol-2-ylamino}-ethanol  
[58] or a pharmaceutically acceptable salt thereof.

**5. (Previously Presented)** The compound of claim 4, wherein said compound is 2-{4-Methyl-5-[2-(3-nitro-phenyl amino)-pyrimidin-4-yl]-thiazol-2-ylamino}-ethanol [58] or a pharmaceutically acceptable salt thereof.

Claims 6-9 (Cancelled).

10. **(Currently Amended)** A compound according to claim 19 which is selected from the group consisting of:

[4-(2-amino-4-methyl-thiazol-5-yl)-pyrimidin-2-yl]-(3-nitro-phenyl)-amine [1];

*N*-{4-Methyl-5-[2-(3-nitro-phenylamino)-pyrimidin-4-yl]-thiazol-2-yl}-methanesulfonamide [56]; and

2-{4-Methyl-5-[2-(3-nitro-phenylamino)-pyrimidin-4-yl]-thiazol-2-ylamino}-ethanol [58]; or a pharmaceutically acceptable salt thereof.

11. **(Currently Amended)** A compound according to claim 19 which is [4-(2-Amino-4-methyl-thiazol-5-yl)-pyrimidin-2-yl]-(3-nitro-phenyl)-amine [1]; or a pharmaceutically acceptable salt thereof.

12. **(Currently Amended)** A pharmaceutical composition comprising a compound according to claim 1 ~~or~~ 6, or a pharmaceutically acceptable salt thereof, together with a pharmaceutically acceptable diluent, excipient or carrier.

13. **(Original)** A pharmaceutical composition according to claim 12 which further comprises one or more other anticancer agents.

14. **(Currently Amended)** A method for treating a CDK-sensitive or CDK-dependent proliferative disorder in a subject, comprising administering one or more compound of claim 1 ~~or~~ 6, or a pharmaceutically acceptable salt thereof, to a subject, such that the subject is treated for a proliferative disorder.

15. **(Original)** The method of claim 14, wherein the proliferative disorder is cancer or leukaemia.

Claim 16 **(Cancelled)**.

17. **(Currently Amended)** The method of claim 14 ~~16~~ wherein ~~the CDK-enzyme is~~ said one or more compounds are administered in an amount sufficient to inhibit CDK2 or CDK4.

18. **(Cancelled)**.

19. **(Previously Presented)** The method of claim 14, wherein said compound is administered in combination with one or more other anticancer agents.
20. **(Previously Presented)** The method of claim 14, wherein said proliferative disorder is lung cancer.
21. **(Previously Presented)** The method of claim 14, wherein said proliferative disorder is colon cancer.
22. **(Previously Presented)** The method of claim 14, wherein said proliferative disorder is bone cancer.